Resetting Aberrant Tregs Epigenetically to Treat Autoimmune Diseases

Shimon Sakaguchi shared the 2025 Nobel Prize in Physiology or Medicine for his identification of regulatory T cells that suppress autoimmune responses. His work laid the foundation for RegCell, a company he co-founded to develop cell therapies that provide targeted treatments for autoimmune disease without compromising healthy immune function. RegCell epigenetically reprograms patient T cells into regulatory T cells. We spoke to Michael McCullar, CEO of RegCell, about the role of dysfunctional Tregs in autoimmune diseases, the firm’s use of epigenetically modified regulatory T cells to treat these conditions, and how this approach can selectively suppress harmful immune responses without causing broad immunosuppression.

You can listen to Resetting Aberrant Tregs Epigenetically to Treat Autoimmune Diseases online on Radio and Podcast. Open the player on this page to stream the available audio.

Resetting Aberrant Tregs Epigenetically to Treat Autoimmune Diseases is an episode from RARECast by RARECast.

This episode is 00:30:19 long.

This episode was published on Jan 29, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from RARECast when more episodes are available from the podcast feed.